课题基金 / 基金详情

项目摘要

项目成果

STEPHEN M ANSELL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The tumor microenvironment plays an important role in non-Hodgkin lymphoma (NHL) and the role intratumoral immune cells play in the pathology of lymphoma has been significantly understated. Intratumoral monocytes and macrophages are particularly important and our data demonstrate that intratumoral monocytes in NHL are highly immunosuppressive and support malignant cell growth. In preliminary work, we found that suppressive monocytic cells (SMCs) are abundant within the peripheral blood and tumor microenvironment in lymphoma patients and promote the survival of lymphoma cells. SMCs protect lymphoma cells from chemotherapy-induced cell death and promote lymphoma cell engraftment into severe combined immunodeficient (SCID) mice. Furthermore, we found that SMCs within lymph nodes express immunosuppressive ligands including B7-H1 (PD-L1, CD273), inhibit normal T-cell proliferation and promote the induction of FoxP3+ regulatory T cells. These preliminary studies suggest that SMCs have an effect on both malignant NHL cells and non-malignant intratumoral T-cells. Based on our results, we hypothesize that the intersection between the immune system and the malignant cell in NHL is the SMCs. In this proposal, we plan to understand whether monocytes are specifically recruited to sites of lymphoma and which specific chemokines could be inhibited to prevent SMC migration; how lymphoma cells induce SMCs to support their malignant cell growth and to suppress the host's antitumor immunity; and whether promoting monocyte/macrophage maturation or inhibiting their interaction with other cells, particularly in the presence of monoclonal antibodies, improves their anti-tumor function. Upon completion of this project, we expect to have a greater understanding of the role of monocytes and their progeny in NHL. Collectively our findings are likely to have a major impact by leading to an effective monocyte-directed therapeutic approach for patients with lymphoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
P4 - Regulatory T-Cells in the Tumor Microenvironment of B-Cell Non-Hodgkin
  • 批准号:
    8076891
  • 项目类别:
  • 资助金额:
    $27.6万
  • 财政年份:
    2010
  • 负责人:
    STEPHEN M ANSELL
  • 依托单位:
Regulatory T-Cells in the Tumor Microenvironment of B-Cell Non-Hodgkin
  • 批准号:
    7254595
  • 项目类别:
  • 资助金额:
    $29.71万
  • 财政年份:
    2007
  • 负责人:
    STEPHEN M ANSELL
  • 依托单位:
BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' Lymphoma
  • 批准号:
    7382530
  • 项目类别:
  • 资助金额:
    $28.12万
  • 财政年份:
    2007
  • 负责人:
    STEPHEN M ANSELL
  • 依托单位:
BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' Lymphoma
  • 批准号:
    7222596
  • 项目类别:
  • 资助金额:
    $28.12万
  • 财政年份:
    2007
  • 负责人:
    STEPHEN M ANSELL
  • 依托单位:
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
  • 批准号:
    82072862
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2020
  • 负责人:
    徐云升
  • 依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
  • 批准号:
    82070825
  • 项目类别:
    面上项目
  • 资助金额:
    53.0万元
  • 批准年份:
    2020
  • 负责人:
    徐西振
  • 依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
  • 批准号:
    81903002
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.5万元
  • 批准年份:
    2019
  • 负责人:
    王斐斐
  • 依托单位: